SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (655)4/29/1997 3:19:00 PM
From: margie   of 6136
 
Continued:

Subj: Re: Financing an increase in Viracept production and sales is not a problem
Date: 29 Apr 1997 13:15:04 EDT
From: LMoss

I meant to add that Agouron already has a marketing staff (more than 100 people) in place and that this staff seems adequate to service the less than 4000 physicians who prescribe the vast majority of antiviral drugs for HIV and AIDS, even should sales levels go well beyond 300,000 patients served. Additional financing is therefore not needed for this purpose.

Rapidly increasing sales do require more financing of accounts receivables, but internal sources along with revenues (though somewhat delayed) from sales are adequate to do this.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News